Company Overview of Apotex Inc.
Apotex Inc., a pharmaceutical company, engages in the research and development, manufacture, distribution, and sale of generic pharmaceuticals in Canada and internationally. It offers medicines in various dosage forms. The company serves patients, healthcare providers, payers, and governments. It offers its products through pharmacies and healthcare facilities. The company was founded in 1974 and is based in Toronto, Canada with additional offices in Saudi Arabia. It has facilities in Montreal, Richmond Hill, Toronto, Etobicoke, Mississauga, Brantford, Windsor, Winnipeg, London, Calgary, and Vancouver, Canada; and subsidiaries, joint ventures, and licensing agreements in Australia, Belgium, ...
150 Signet Drive
Toronto, ON M9L 1T9
Founded in 1974
Key Executives for Apotex Inc.
Founder and Chairman of the Board
President of Apotex International
Director of Research and Development
Director of Marketing -Canada
Compensation as of Fiscal Year 2013.
Apotex Inc. Key Developments
Pfizer Inc. Appeal Court Decision Regarding Celebrex Reissue Patent Against Teva Pharmaceuticals USA, Inc., Mylan Pharmaceuticals Inc., Watson Laboratories, Inc., Lupin Pharmaceuticals, USA, Inc., Apotex Corp., and Apotex, Inc
Mar 12 14
Pfizer Inc. confirmed that the United States District Court for the Eastern District of Virginia granted summary judgment invalidating the reissue patent (U.S. Patent No. RE44,048), covering methods of treating osteoarthritis and other approved conditions with celecoxib, the active ingredient in Celebrex(R). Pfizer disagrees with the ruling and will pursue all available remedies, including an immediate appeal of the court's decision. A trial was scheduled to begin on March 19, 2014, for infringement of the reissue patent in the action brought by Pfizer against the generic companies Teva Pharmaceuticals USA, Inc., Mylan Pharmaceuticals Inc., Watson Laboratories, Inc., Lupin Pharmaceuticals, USA, Inc., Apotex Corp., and Apotex, Inc. Each of these generic companies previously filed an abbreviated new drug application with the United States Food and Drug Administration seeking approval to market a generic form of celecoxib in the United States beginning on May 30, 2014, when Pfizer's basic Celebrex(R) compound patent (including the six-month pediatric exclusivity period) expires. This is eighteen months prior to the December 2, 2015 expiration (including the six-month pediatric exclusivity period) of the reissue patent.
Ferring Pharmaceuticals Inc. Receives Positive Verdict in Patent Infringement Lawsuit for LYSTEDA(R) (tranexamic acid)
Feb 3 14
Ferring Pharmaceuticals Inc. announced that their patents for LYSTEDA(R) (tranexamic acid), a non-hormonal prescription medicine to treat heavy monthly menstrual bleeding, have been found valid and infringed by both Watson Pharmaceuticals Inc. (Watson) and Apotex Inc. The separate lawsuits against Watson and Apotex were filed by Ferring in July 2011 and alleged that the Abbreviated New Drug Applications (ANDAs) filed by each for tranexamic acid tablets, the generic equivalent to LYSTEDA, infringe Ferring's patents for the product. The positive verdicts by the court confirm LYSTEDA's exclusivity. Watson and Apotex can appeal the decisions and/or attempt to amend their respective ANDAs that exclude infringing products.
Apotex Inc. Open Three New Offices in Jeddah, Riyadh and Dammam, Saudi Arabia
Dec 12 13
Apotex Inc. has opened new offices in Jeddah, Riyadh and Dammam, Saudi Arabia. Currently, the three Apotex sites are operating with 41 new employees with plans to expand these numbers in the future.
Similar Private Companies By Industry
Recent Private Companies Transactions